Topics

Proposed Herceptin biosimilar to be marketed by Sandoz

11:41 EDT 2 May 2019 | BioPharma-Reporter

Sandoz inks agreement with EirGenix to commercialize a Herceptin biosimilar currently in late-stage development.

Original Article: Proposed Herceptin biosimilar to be marketed by Sandoz

NEXT ARTICLE

More From BioPortfolio on "Proposed Herceptin biosimilar to be marketed by Sandoz"

Quick Search

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...